

## Un-audited Financial Results for the Quarter ended 30.09.2010

(₹ in Lacs)

S. No.	PARTICULARS	Quarter ended 30.09.2010	Quarter ended 30.09.2009	Half Year Ended 30.09.2010	Half Year Ended 30.09.2009	Year Ended 31.03.2010
		Un-audited	Un-audited	Un-audited	Un-audited	Audited
1.	<b>Gross Sales/Income from Operations</b>	23007.59	26426.50	42145.66	46780.00	88582.17
	Less : Excise Duty	1435.03	1050.97	2448.27	2225.19	4002.26
	Net Sales / Income from Operations	21572.56	25375.53	39697.39	44554.81	84579.91
	Other Operating Income	129.21	46.00	208.72	135.00	409.59
	<b>Total Operating Income</b>	<b>21701.77</b>	<b>25420.53</b>	<b>39906.11</b>	<b>44689.81</b>	<b>84989.50</b>
2.	<b>Expenditure</b>					
	a. (Increase)/decrease in stock in trade	(1355.33)	118.30	(1688.18)	738.75	939.51
	b. Consumption of Raw Material	14706.96	17581.02	26227.41	29499.83	53491.67
	c. Employees Cost	901.38	800.97	1778.08	1574.92	3187.70
	d. Depreciation	1145.55	1012.76	2271.19	1915.02	3874.64
	e. Other Expenditure	2015.49	1955.91	3669.23	3454.67	7457.01
	<b>Total Expenditure</b>	<b>17414.05</b>	<b>21468.96</b>	<b>32257.73</b>	<b>37183.19</b>	<b>68950.53</b>
3.	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items (1-2)</b>	<b>4287.72</b>	<b>3951.57</b>	<b>7648.38</b>	<b>7506.62</b>	<b>16038.97</b>
4.	Other Income	0.71	101.13	5.71	150.41	1485.73
5.	<b>Profit before Interest &amp; Exceptional Items (3+4)</b>	<b>4288.43</b>	<b>4052.70</b>	<b>7654.09</b>	<b>7657.03</b>	<b>17524.70</b>
6.	Interest	1341.78	1143.06	2618.37	2702.92	6028.44
7.	<b>Profit after Interest but before Exceptional Items (5-6)</b>	<b>2946.65</b>	<b>2909.64</b>	<b>5035.72</b>	<b>4954.11</b>	<b>11496.26</b>
8.	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9.	<b>Profit from ordinary activities before tax (7+8)</b>	<b>2946.65</b>	<b>2909.64</b>	<b>5035.72</b>	<b>4954.11</b>	<b>11496.26</b>
10.	<b>Tax Expenses</b>					
	Current Tax	587.48	494.49	1003.64	841.95	1953.51
	Mat Credit Entitlement	(337.28)	(494.49)	(447.28)	(841.95)	(725.06)
	Deferred tax	281.20	0.00	496.16	0.00	1000.20
	Excess Provision for taxation written back	0.00	0.00	0.00	0.00	70.17
11.	<b>Net Profit from ordinary activities after tax (9-10)</b>	<b>2415.25</b>	<b>2909.64</b>	<b>3983.20</b>	<b>4954.11</b>	<b>9197.44</b>
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13.	<b>Net Profit for the period (11-12)</b>	<b>2415.25</b>	<b>2909.64</b>	<b>3983.20</b>	<b>4954.11</b>	<b>9197.44</b>
14.	Paid up Equity Share Capital ( Face Value per share : ₹ 1/-)	2242.61	1522.61	2242.61	1522.61	2242.61
15.	Reserves excluding Revaluation Reserves					59855.37
16.	<b>Earnings per Share (EPS)</b>					
	Basic EPS before Extraordinary items	1.08	1.91	1.78	3.25	5.81
	Diluted EPS before Extraordinary items	0.86	1.39	1.41	2.37	4.28
	Basic EPS after Extraordinary items	1.08	1.91	1.78	3.25	5.81
	Diluted EPS after Extraordinary items	0.86	1.39	1.41	2.37	4.28
17.	<b>Public Shareholding</b>					
	- Number of Shares	125971970	54119330	125971970	54119330	126119330
	- Percentage of Shareholding	56.24	35.54	56.24	35.54	56.24
18.	<b>Promoters and Promoter Group Shareholding</b>					
	<b>a) Pledged/Encumbered</b>					
	- Number of Shares	0	0	0	0	0
	- Percentage of Shares ( as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00
	- Percentage of Shares ( as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00
	<b>b) Non-encumbered</b>					
	- Number of Shares	98289000	98141640	98289000	98141640	98141640
	- Percentage of Shares ( as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares ( as a % of the total share capital of the company)	43.83	64.46	43.83	64.46	43.76
<b>Statement of Assets and Liabilities</b> (₹ in Lacs)						
				<b>Unaudited</b>	<b>Unaudited</b>	<b>Audited</b>
<b>SHAREHOLDERS' FUND</b>						
(a) Capital				2242.61	1522.61	2242.61
(b) Reserves and Surplus				63001.40	33743.90	59855.37
<b>LOAN FUNDS</b>				67164.76	78460.66	60089.22
<b>DEFERRED TAX LIABILITY</b>				<b>5514.75</b>	<b>4018.39</b>	<b>5018.59</b>
				<b>Total</b>	<b>137923.52</b>	<b>117745.56</b>
<b>FIXED ASSETS (inclusive of Capital W.I.P.)</b>				72170.36	66027.84	68277.36
<b>INVESTMENTS</b>				569.29	507.57	2569.29
<b>CURRENT ASSETS, LOANS &amp; ADVANCES</b>						
(a) Inventories				44196.33	37411.82	39635.36
(b) Sundry Debtors				24840.85	18905.58	22245.45
(c) Cash and Bank balances				2124.32	622.90	3051.72
(d) Other Current Assets				2700.71	2248.56	2646.56
(e) Loans and Advances				10143.43	8796.54	9644.01
Less: Current Liabilities and Provisions						
(a) Current Liabilities				11557.77	11559.95	14371.41
(b) Provisions				7267.38	5242.65	6496.30
<b>Miscellaneous Expenditure (Not written off or adjusted)</b>				3.38	27.35	3.75
<b>PROFIT AND LOSS ACCOUNT</b>				0.00	0.00	0.00
				<b>Total</b>	<b>137923.52</b>	<b>117745.56</b>

- Notes :** 1. The above financial results were reviewed by Audit Committee on 08.11.10 and approved by the Board in its meeting held on even date i.e. 08.11.10
2. The above financial results are on stand alone basis.
3. The company is exclusively in the pharmaceutical business segment.
4. The Company has allotted 26,000,000 equity shares on preferential basis on 20.02.2010 to non-promoters and 46,000,000 equity shares underlying Global Depository Receipts (GDRs) on 26.02.2010. After said allotments, the paid up equity capital of the company stands increased from ₹ 152,260,970/- to ₹ 224,260,970/- comprising of 224,260,970 equity shares of ₹ 1/- each. This is the reason of decrease in the %age of holding of the promoters, increase in the public shareholding and decrease in EPS.
5. The quarter and half year under review sales and Yearly Audited sales does not include any Inter-Unit Sales. However, Corresponding previous quarter and half year sales includes Inter unit sales of ₹ 5959 Lacs and ₹ 8349 lacs respectively.
6. The Provision for Tax in the quarter and half year under review includes current tax and deferred tax to the extent of ₹ 531.40 lacs and ₹ 1052.52 lacs respectively. However corresponding previous quarter and half year figures did not include provision for deferred tax, which was subsequently accounted for in the audited financial results of 31st March, 2010.
7. Status of Complaints: a) Pending at the beginning of Quarter - Nil b) Received During the Quarter - 7  
c) Disposed Off During the Quarter - 7 d) Pending at the end of Quarter - Nil

**By Order of the Board of Directors  
of Nectar Lifesciences Limited**

Sd/-

(Dinesh Dua)  
Chief Executive Officer & Director

Dated : 08.11.2010  
Place : Chandigarh